A small molecule inhibitor of RAD51 reduces homologous recombination and sensitizes multiple myeloma cells to doxorubicin

Frontiers in Oncology

Volumn 4, Issue OCT, 2014, Pages

  Alagpulinsa, David A ^a,b   Ayyadevara, Srinivas ^a,b   Shmookler Reis, Robert J ^a,b  

^a CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

B02; Chemoresistance; Doxorubicin; H2AX; Homologous recombination; Multiple myeloma; RAD51; Recombinase

Indexed keywords

DOXORUBICIN; HISTONE H3; PROTEIN INHIBITOR; RAD51 INHIBITOR; RAD51 PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL VIABILITY; COLONY FORMATION; CONTROLLED STUDY; DOUBLE STRANDED DNA BREAK; FLOW CYTOMETRY; GENE DISRUPTION; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; MULTIPLE MYELOMA; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING;

EID: 84907851334     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00289     Document Type: Article

References (53)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin (2014) 64:9-29.
2. Bergsagel PL, Kuehl WM. Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol (2005) 23:6333-6338. doi: 10.1200/JCO.2005.05.021.
3. Chapman MA, Lawrence MS, Keats JJ, Cibulskis K, Sougnez C, Schinzel AC, et al. Initial genome sequencing and analysis of multiple myeloma. Nature (2011) 471:467-472. doi: 10.1038/nature09837.
4. Shammas MA, Shmookler Reis RJ, Koley H, Batchu RB, Li C, Munshi NC. Dysfunctional homologous recombination mediates genomic instability and progression in myeloma. Blood (2009) 113:2290-2297. doi: 10.1182/blood-2007-05-089193.
5. Long DT, Raschle M, Joukov V, Walter JC. Mechanism of RAD51-dependent DNA interstrand crosslink repair. Science (2011) 333:84-87. doi: 10.1126/science.1204258.
6. Sung P, Klein H. Mechanism of homologous recombination: mediators and helicases take on regulatory functions. Nat Rev Mol Cell Biol (2006) 7:739-750. doi: 10. 1038/nrm2008.
7. Sung P. Catalysis of ATP-dependent homologous DNA pairing and strand exchange by yeast RAD51 protein. Science (1994) 265:1241-1243.
8. Baumann P, Benson FE, West SC. Human Rad51 protein promotes ATP-dependent homologous pairing and strand transfer reactions in vitro. Cell (1996) 87:757-766.
9. Lambert S, Lopez BS. Role of RAD51 in sister-chromatid exchanges in mammalian cells. Oncogene (2001) 20:6627-6631. doi: 10.1038/sj.onc.1204813.
10. Maacke H, Opitz S, Jost K, Hamdorf W, Henning W, Kruger S, et al. Over-expression of wild-type Rad51 correlates with histological grading of invasive ductal breast cancer. Int J Cancer (2000) 88:907-913.
11. Mitra A, Jameson C, Barbachano Y, Sanchez L, Kote-Jarai Z, Peock S, et al. Overexpression of RAD51 occurs in aggressive prostatic cancer. Histopathology (2009) 55:696-704. doi: 10.1111/j.1365-2559.2009.03448.x.
12. Li Y, Yu H, Luo RZ, Zhang Y, Zhang MF, Wang X, et al. Elevated expression of Rad51 is correlated with decreased survival in resectable esophageal squamous cell carcinoma. J Surg Oncol (2011) 104:617-622. doi: 10.1002/jso.22018.
13. Connell P, Jayathilaka K, Haraf DJ, Weichselbaum R, Vokes E, Lingen M. Pilot study examining tumor expression of RAD51 and clinical outcomes in human head cancers. Int J Oncol (2006) 28:1113-1119.
14. Qiao GB, Wu YL, Yang XN, Zhong WZ, Xie D, Guan XY, et al. High-level expression of Rad51 is an independent prognostic marker of survival in non-small-cell lung cancer patients. Br J Cancer (2005) 93:137-143. doi: 10.1038/sj.bjc.6602665.
15. Tennstedt P, Fresow R, Simon R, Marx A, Terracciano L, Petersen C, et al. RAD51 overexpression is a negative prognostic marker for colorectal adenocarcinoma. Int J Cancer (2013) 132:2118-2126. doi: 10.1002/ijc.27907.
16. Barbano R, Copetti M, Perrone G, Pazienza V, Muscarella LA, Balsamo T, et al. High RAD51 mRNA expression characterize estrogen receptor-positive/progesteron receptor-negative breast cancer and is associated with patient's outcome. Int J Cancer (2011) 129(3):536-45. doi: 10.1002/ijc.25736.
17. Hansen LT, Lundin C, Spang-Thomsen M, Petersen LN, Helleday T. The role of RAD51 in etoposide (VP16) resistance in small cell lung cancer. Int J Cancer (2003) 105:472-479. doi: 10.1002/ijc.11106.
18. Takenaka T, Yoshino I, Kouso H, Ohba T, Yohena T, Osoegawa A, et al. Combined evaluation of Rad51 and ERCC1 expressions for sensitivity to platinum agents in non-small cell lung cancer. Int J Cancer (2007) 121:895-900. doi: 10.1002/ijc.22738.
19. Hannay JA, Liu J, Zhu QS, Bolshakov SV, Li L, Pisters PW, et al. Rad51 overexpression contributes to chemoresistance in human soft tissue sarcoma cells: a role for p53/activator protein 2 transcriptional regulation. Mol Cancer Ther (2007) 6:1650-1660. doi: 10.1158/1535-7163.MCT-06-0636.
20. Yang Z, Waldman AS, Wyatt MD. Expression and regulation of RAD51 mediate cellular responses to chemotherapeutics. Biochem Pharmacol (2012) 83:741-746. doi: 10.1016/j.bcp.2011.12.022.
21. Xu ZY, Loignon M, Han FY, Panasci L, Aloyz R. Xrcc3 induces cisplatin resistance by stimulation of Rad51-related recombinational repair, S-phase checkpoint activation, and reduced apoptosis. J Pharmacol Exp Ther (2005) 314:495-505. doi: 10.1124/jpet.105.084053.
22. Vispe S, Cazaux C, Lesca C, Defais M. Overexpression of Rad51 protein stimulates homologous recombination and increases resistance of mammalian cells to ionizing radiation. Nucleic Acids Res (1998) 26:2859-2864.
23. Kassambara A, Gourzones-Dmitriev C, Sahota S, Reme T, Moreaux J, Goldschmidt H, et al. A DNA repair pathway score predicts survival in human multiple myeloma: the potential for therapeutic strategy. Oncotarget (2014). 5:2487-2498.
24. Ito M, Yamamoto S, Nimura K, Hiraoka K, Tamai K, Kaneda Y. Rad51 siRNA delivered by HVJ envelope vector enhances the anti-cancer effect of cisplatin. J Gene Med (2005) 7:1044-1052. doi: 10.1002/jgm.753.
25. Downes CS, Clarke DJ, Mullinger AM, Gimenez-Abian JF, Creighton AM, Johnson RT. A topoisomerase II-dependent G2 cycle checkpoint in mammalian cells. Nature (1994) 372:467-470. doi: 10.1038/372467a0.
26. Hawtin RE, Stockett DE, Wong OK, Lundin C, Helleday T, Fox JA. Homologous recombination repair is essential for repair of vosaroxin-induced DNA double-strand breaks. Oncotarget (2010) 1:606-619.
27. Spencer DM, Bilardi RA, Koch TH, Post GC, Nafie JW, Kimura K, et al. DNA repair in response to anthracycline-DNA adducts: a role for both homologous recombination and nucleotide excision repair. Mutat Res (2008) 638:110-121.
28. Yang C, Betti C, Singh S, Toor A, Vaughan A. Impaired NHEJ function in multiple myeloma. Mutat Res (2009) 660:66-73. doi: 10.1016/j.mrfmmm.2008.10.019.
29. Neri P, Ren L, Gratton K, Stebner E, Johnson J, Klimowicz A, et al. Bortezomib-induced "BRCAness" sensitizes multiple myeloma cells to PARP inhibitors. Blood (2011) 118:6368-6379. doi: 10.1182/blood-2011-06-363911.
30. Chen X, Wong P, Radany EH, Stark JM, Laulier C, Wong JY. Suberoylanilide Hydroxamic acid as a radiosensitizer through modulation of RAD51 protein and inhibition of homology-directed repair in multiple myeloma. Mol Cancer Res (2012). 10:1052-1064. doi: 10.1158/1541-7786.MCR-11-0587.
31. Huang F, Motlekar NA, Burgwin CM, Napper AD, Diamond SL, Mazin AV. Identification of specific inhibitors of human RAD51 recombinase using high-throughput screening. ACS Chem Biol (2011) 6:628-635. doi: 10.1021/cb100428c.
32. Huang F, Mazin OM, Zentner IJ, Cocklin S, Mazin AV. Inhibition of homologous recombination in human cells by targeting RAD51 recombinase. J Med Chem (2012). 55:3011-3020. doi: 10.1021/jm201173g.
33. Huang F, Mazin AV. A small molecule inhibitor of human RAD51 potentiates breast cancer cell killing by therapeutic agents in mouse xenografts. PLoS One (2014). 9:1-12.
34. Maes K, De Smedt E, Lemaire M, De Raeve H, Menu E, Van Valckenborgh E, et al. The role of DNA damage and repair in decitabine-mediated apoptosis in multiple myeloma. Oncotarget (2014) 5:3115-3129.
35. Pierce AJ, Johnson RD, Thompson LH, Jasin M. XRCC3 promotes homology-directed repair of DNA damage in mammalian cells. Genes Dev (1999) 13:2633-2638.
36. Anglana M, Bacchetti S. Construction of a recombinant adenovirus for efficient delivery of the I-SceI yeast endonuclease to human cells and its application in the in vivo cleavage of chromosomes to expose new potential telomeres. Nucleic Acids Res (1999) 27:4276-4281.
37. Rothkamm K, Kruger I, Thompson LH, Lobrich M. Pathways of DNA double-strand break repair during the mammalian cell cycle. Mol Cell Biol (2003) 23:5706-5715.
38. Yamamoto A, Taki T, Yagi H, Habu T, Yoshida K, Yoshimura Y, et al. Cell cycle-dependent expression of the mouse Rad51 gene in proliferating cells. Mol Gen Genet (1996) 251:1-12.
39. Raderschall E, Bazarov A, Cao J, Lurz R, Smith A, Mann W, et al. Formation of higher-order nuclear Rad51 structures is functionally linked to p21 expression and protection from DNA damage-induced apoptosis. J Cell Sci (2002) 115(Pt 1):153-164.
40. Johnson N, Cai D, Kennedy RD, Pathania S, Arora M, Li YC, et al. Cdk1 participates in BRCA1-dependent S phase checkpoint control in response to DNA damage. Mol Cell (2009) 35:327-339. doi: 10.1016/j.molcel.2009.06.036.
41. Krishan A, Frei E, 3rd. Effect of adriamycin on the cell cycle traverse and kinetics of cultured human lymphoblasts. Cancer Res (1976) 36:143-150.
42. Koehn H, Magan N, Isaacs RJ, Stowell KM. Differential regulation of DNA repair protein Rad51 in human tumour cell lines exposed to doxorubicin. Anticancer Drugs (2007) 18:419-425. doi: 10.1097/CAD.0b013e328012a9a0.
43. Yang Z, Waldman AS, Wyatt MD. Expression and regulation of RAD51 mediate cellular responses to chemotherapeutics. Biochem Pharmacol (2012). 83:741-746. doi: 10.1016/j.bcp.2011.12.022.
44. Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem (1998) 273:5858-5868.
45. Graeser M, McCarthy A, Lord CJ, Savage K, Hills M, Salter J, et al. A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer. Clin Cancer Res (2010) 16:6159-6168. doi: 10.1158/1078-0432.CCR-10-1027.
46. Carvalho JF, Kanaar R. Targeting homologous recombination-mediated DNA repair in cancer. Expert Opin Ther Targets (2014). 18:427-458. doi: 10.1517/14728222.2014.882900.
47. Chen X, Wong P, Radany EH, Stark JM, Laulier C, Wong JY. Suberoylanilide hydroxamic acid as radiosensitizer through modulation of RAD51 protein and inhibition of homology-directed repair in multiple myeloma. Mol Cancer Res (2012). 10:1052-1064. doi: 10.1158/1541-7786.MCR-11-0587.
48. Vejpongsa P, Yeh ET. Topoisomerase 2beta: a promising molecular target for primary prevention of anthracycline-induced cardiotoxicity. Clin Pharmacol Ther (2014) 95(1):45-52.
49. Potter AJ, Gollahon KA, Palanca BJ, Harbert MJ, Choi YM, Moskovitz AH, et al. Flow cytometric analysis of the cell cycle phase specificity of DNA damage induced by radiation, hydrogen peroxide and doxorubicin. Carcinogenesis (2002) 23:389-401.
50. Tyagi AK, Singh RP, Agarwal C, Chan DC, Agarwal R. Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth Inhibition, G2-M arrest, and apoptosis. Clin Cancer Res (2002) 8:3512-3519.
51. Henning W, Stürzbecher H-W. Homologous recombination and cell cycle checkpoints: Rad51 in tumour progression and therapy resistance. Toxicology (2003) 193:91-109. doi: 10.1016/s0300-483x(03)00291-9.
52. Finn GK, Kurz BW, Cheng RZ, Shmookler Reis RJ: Homologous plasmid recombination is elevated in immortally transformed cells. Mol Cell Biol (1989) 9: 4009-4017.
53. Xia SJ, Shammas MA, and Shmookler Reis RJ: Elevated recombination in immortal human cells is mediated by HsRAD51 recombinase. Mol Cell Biol (1997) 17: 7151-7158.